MBCOF (Marvel Biosciences) 5-Year RORE % : -29.66% (As of Apr. 2026)


MBCOF Marvel Biosciences Corp MBCOF
34 GF Score
Price $0.11
! 1 Warning Sign
View Full Analysis

What is Marvel Biosciences 5-Year RORE %?

Marvel Biosciences MBCOF 34 5-Year RORE % is -29.66 as of Apr. 2026. GuruFocus rates MBCOF with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,137 Biotechnology companies, Marvel Biosciences ranks worse than 71.24% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Marvel Biosciences's 5-Year RORE % for the quarter that ended in Apr. 2026 was -29.66%.

The industry rank for Marvel Biosciences's 5-Year RORE % or its related term are showing as below:

MBCOF's 5-Year RORE % is ranked worse than
71.24% of 1137 companies
in the Biotechnology industry
Industry Median: -10.66 vs MBCOF: -29.66

Marvel Biosciences  (OTCPK:MBCOF) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Marvel Biosciences 5-Year RORE % Related Terms


Marvel Biosciences 5-Year RORE % Historical Data

* Premium members only.

The historical data trend for Marvel Biosciences's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marvel Biosciences 5-Year RORE % Chart

Marvel Biosciences Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
5-Year RORE %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -11.95

Marvel Biosciences Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.62 -11.95 -15.20 -22.92 -29.66

MBCOF vs VRTX, REGN, ALNY: 5-Year RORE % Comparison

For the Biotechnology subindustry, Marvel Biosciences's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marvel Biosciences 5-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marvel Biosciences's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Marvel Biosciences's 5-Year RORE % falls into.


MBCOF
34GF Score
Marvel Biosciences Corp MBCOF
5-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marvel Biosciences 5-Year RORE % Calculation

Marvel Biosciences's 5-Year RORE % for the quarter that ended in Apr. 2026 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( -0.029--0.099 )/( -0.236-0 )
=0.07/-0.236
=-29.66 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Apr. 2026 and 5-year before.

Frequently Asked Questions Learn more about 5-Year RORE % →
What does a 5-Year RORE % of -29.66 mean?
Marvel Biosciences (MBCOF) has a 5-Year RORE % of -29.66 as of Apr. 2026. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Marvel Biosciences and its competitors. According to the industry distribution chart, Marvel Biosciences ranks #810 out of 1137 companies in the Biotechnology industry, placing it in the top 71.2%.
Is Marvel Biosciences' 5-Year RORE % too high?
Marvel Biosciences' current 5-Year RORE % is -29.66. Based on the distribution chart, Marvel Biosciences ranks #810 out of 1137 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Marvel Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Marvel Biosciences' 5-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Marvel Biosciences ranks #810 out of 1137 companies for 5-Year RORE %. This places Marvel Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Biotechnology company?
A good 5-Year RORE % depends on the Biotechnology industry context. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Marvel Biosciences and its competitors. Marvel Biosciences's current 5-Year RORE % is -29.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marvel Biosciences stock overvalued right now?
Marvel Biosciences (MBCOF) has a current 5-Year RORE % of -29.66. The current 5-Year RORE % is -29.66. Marvel Biosciences' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For Marvel Biosciences (MBCOF), the current 5-Year RORE % is -29.66 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Marvel Biosciences Business Description

Other Exchanges MRVL:Canada
Address 505 - 8th Avenue SW, Suite 420, Calgary, AB, CAN, T2P1G2
Marvel Biosciences Corp is a biotechnology company incorporated in Canada. The Company is currently a pre-clinical stage pharmaceutical development company that utilizes a drug redevelopment approach to identify and evaluate potential therapeutic compounds. Its activities mainly involve scientific research and pre-clinical studies aimed at determining viable active compounds for further drug development.
34GF Score

Get the complete analysis for MBCOF

5-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.11
Price